Disease · EFO_1001012
leptomeningeal metastasis
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. leptomeningeal metastasis. Diseases, record EFO_1001012. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_1001012
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Meningeal Carcinomatosis, leptomeningeal metastases, malignant meningitis (disorder), metastatic malignant neoplasm in the Leptomeninges, metastatic tumor to the Leptomeninges
- Open Targets
Drugs44
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METHOTREXATE | CHEMBL34259 | Small molecule | Approval | DailyMed | 7 | 6 | 6 | Drugs and targets |
| CYTARABINE | CHEMBL803 | Small molecule | Approval | DailyMed | 6 | 5 | 5 | Drugs and targets |
| METHOTREXATE SODIUM | CHEMBL3244648 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| OMBURTAMAB | CHEMBL4297233 | Antibody | Phase 2/3 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| PEMETREXED | CHEMBL225072 | Small molecule | Phase 2 | ClinicalTrials.gov | 25 | 25 | 25 | Drugs and targets |
| OSIMERTINIB | CHEMBL3353410 | Small molecule | Phase 2 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| BEVACIZUMAB | CHEMBL1201583 | Antibody | Phase 2 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| FIRMONERTINIB | CHEMBL4297258 | Small molecule | Phase 2 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| AUMOLERTINIB | CHEMBL4761468 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 44
See all 44 drugsTargets41
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 7 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 6 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| DHFR | Dihydrofolate reductase | 4 | Dihydrofolate reductase inhibitor | Approval | https://conductscience.org/library/genes/1719 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 4 | Receptor protein-tyrosine kinase erbB-2 binding agent; Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| TYMS | Thymidylate synthase | 3 | Thymidylate synthase inhibitor | Phase 2 | https://conductscience.org/library/genes/7298 | Drugs and targets |
| CTLA4 | Cytotoxic T-lymphocyte protein 4 | 2 | Cytotoxic T-lymphocyte protein 4 inhibitor | Phase 2 | https://conductscience.org/library/genes/1493 | Drugs and targets |
| GART | Trifunctional purine biosynthetic protein adenosine-3 | 2 | GAR transformylase inhibitor | Phase 2 | https://conductscience.org/library/genes/2618 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 2 | DNA topoisomerase I inhibitor | Phase 1/2 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TOP2A | DNA topoisomerase 2-alpha | 2 | DNA topoisomerase II alpha inhibitor; DNA topoisomerase II inhibitor | Phase 2 | https://conductscience.org/library/genes/7153 | Drugs and targets |
| AGER | Advanced glycosylation end product-specific receptor | 1 | Advanced glycosylation end product-specific receptor antagonist | Phase 1 | https://conductscience.org/library/genes/177 | Drugs and targets |
1 to 10 of 41
See all 41 targetsTrials70
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 3 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03275402 | 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases | Phase 2/3 | 52 | 2024-02-13 | Neuroblastoma, CNS Metastases, Leptomeningeal Metastases | OMBURTAMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02616393 | Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases | Phase 2 | 36 | 2021-11-23 | Non-Small Cell Lung Cancer, Leptomeningeal Metastases, Brain Metastases | TESEVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02939300 | Ipilimumab and Nivolumab in Leptomeningeal Metastases | Phase 2 | 18 | 2022-11-14 | Leptomeningeal Carcinomatosis | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03501979 | Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD | Phase 2 | 17 | 2023-02-08 | Metastatic Breast Cancer, Leptomeningeal Disease | CAPECITABINE, TRASTUZUMAB, TUCATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT03091478 | Pembrolizumab in Patients With Leptomeningeal Disease | Phase 2 | 13 | 2021-01-26 | Patients With Leptomeningeal Disease | PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00992602 | Liposomal Cytarabine and High-Dose Methotrexate in Treating Patients With Central Nervous System Metastases From Breast Cancer | Phase 2 | 3 | 2017-07-07 | Central Nervous System Metastases, Leptomeningeal Metastases, Recurrent Breast Cancer, Stage IV Breast Cancer, Tumors Metastatic to Brain | CYTARABINE, METHOTREXATE | Its record names the disease | ClinicalTrials.gov |
| NCT07134153 | Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metastases | Phase 1/2 | 139 | Breast Cancer | TRASTUZUMAB DERUXTECAN | Its record names the disease | ClinicalTrials.gov | |
| NCT02228369 | Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer | Phase 1 | 108 | EGFR Mutation Positive Advanced Non Small Cell Lung Cancer | AZD-3759, OSIMERTINIB | Its record names the disease | ClinicalTrials.gov | |
| NCT05305885 | Intra-pemetrexed Alone or Combined With Concurrent Radiotherapy for Leptomeningeal Metastasis | Not applicable | 100 | Leptomeningeal Metastasis | PEMETREXED | Its record names the disease | ClinicalTrials.gov | |
| NCT06304441 | Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer | Not applicable | 100 | Leptomeningeal Metastasis | OSIMERTINIB, PEMETREXED | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 70
See all 70 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials115
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_1001012
GET https://conductscience.org/api/diseases/v1/EFO_1001012/drugs?page=2